Graham Paget
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Graham Paget has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Dickens
Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
2 shared publications - Nina Elisabeth Diana
Division of Nephrology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2 shared publications - Raquel Duarte
Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
2 shared publications - Therese Dix-Peek
University of the Witwatersrand
2 shared publications - Adam Mahomed
University of the Witwatersrand
1 shared publication - Alfred Meremo
Department of Internal Medicine, School of Medicine, the University of Dodoma, Dodoma, Tanzania
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 236
Associations of Transforming Growth Factor-β (TGF-β) with Chronic Kidney Disease Progression in Patients Attending a Tertiary Hospital in Johannesburg, South Africa
Introduction: The global prevalence of chronic kidney disease (CKD) is increasing and it is associated with higher mortality rates. Transforming growth factor-beta (TGF-β) can serve as a novel biomarker for early prediction of chronic kidney disease (CKD) progression. Methods: This was a prospective longitudinal study among black patients with CKD who attended the Charlotte Maxeke Johannesburg Academic Hospital between September 2019 and March 2022. Patients provided urine and blood samples for laboratory investigations at study entry (0) and at 24 months follow up. Baseline serum and urine TGF-β1, TGF-β2 and TGF-β3 levels were measured using ELISAs. Multivariable logistic regression analysis was utilized to determine if TGF-β isoforms could predict CKD progression. Results: A total of 312 patients were enrolled at baseline, of whom 275 (88.1%) had early-stage CKD (Stage 1–3). A majority, 95.2% (297/312), of the patients completed the study after 2 years follow up. The prevalence of CKD progression was 47.8% when measured by a sustained decline in eGFR of >4 mL/min/1.73 m2/year or more and 51.9% when measured by a change in uPCR > 30%. The patients with CKD progression had significantly lower eGFR and increased urine protein–creatinine ratios compared to non-progressors. Furthermore, comparing progressors with non-progressors, the median serum TGF-β1 was 21210 (15915–25745) ng/L vs. 24200 (17570–29560) ng/L and the median urine TGF-β3 was 17.5 (5.4–76.2) ng/L vs. 2.8 (1.8–15.3) ng/L, respectively. Baseline serum and urine TGF-β isoforms were unable to discriminate between CKD progressors and non-progressors after multivariable logistic regression analysis. Conclusions: Despite the multiple roles of TGF-β isoforms in kidney disease, baseline levels were not predictive of chronic kidney disease progression.
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 236
Open AccessAssociations of Transforming Growth Factor-β (TGF-β) with Chronic Kidney Disease Progression in Patients Attending a Tertiary Hospital in Johannesburg, South Africa
Introduction: The global prevalence of chronic kidney disease (CKD) is increasing and it is associated with higher mortality rates. Transforming growth factor-beta (TGF-β) can serve as a novel biomarker for early prediction of chronic kidney disease (CKD) progression. Methods: This was a prospective longitudinal study among black patients with CKD who attended the Charlotte Maxeke Johannesburg Academic Hospital between September 2019 and March 2022. Patients provided urine and blood samples for laboratory investigations at study entry (0) and at 24 months follow up. Baseline serum and urine TGF-β1, TGF-β2 and TGF-β3 levels were measured using ELISAs. Multivariable logistic regression analysis was utilized to determine if TGF-β isoforms could predict CKD progression. Results: A total of 312 patients were enrolled at baseline, of whom 275 (88.1%) had early-stage CKD (Stage 1–3). A majority, 95.2% (297/312), of the patients completed the study after 2 years follow up. The prevalence of CKD progression was 47.8% when measured by a sustained decline in eGFR of >4 mL/min/1.73 m2/year or more and 51.9% when measured by a change in uPCR > 30%. The patients with CKD progression had significantly lower eGFR and increased urine protein–creatinine ratios compared to non-progressors. Furthermore, comparing progressors with non-progressors, the median serum TGF-β1 was 21210 (15915–25745) ng/L vs. 24200 (17570–29560) ng/L and the median urine TGF-β3 was 17.5 (5.4–76.2) ng/L vs. 2.8 (1.8–15.3) ng/L, respectively. Baseline serum and urine TGF-β isoforms were unable to discriminate between CKD progressors and non-progressors after multivariable logistic regression analysis. Conclusions: Despite the multiple roles of TGF-β isoforms in kidney disease, baseline levels were not predictive of chronic kidney disease progression.
- Open Access
- 21 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 132
Clinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review
Background: Kidney transplantation outcomes in resource-limited settings remain underreported. This 10-year retrospective review examined the clinical characteristics, long-term pharmacokinetics, and outcomes of kidney transplant recipients at a South African public hospital. Methods: Data from kidney transplant recipients between January 2012 and December 2022 were analysed. Graft and patient survival were assessed using Kaplan–Meier analysis. Cox proportional hazards models were used to evaluate the associations between clinical and pharmacokinetic variables and outcomes. Results: The one- and five-year graft survival rates were 87.9% and 65.6%, respectively. Acute rejection, as confirmed by biopsy, was associated with graft failure (HR, 2.46; p = 0.010). Increasing recipient age at transplantation increased the graft failure risk by about 5.0% per year (HR: 1.05, p = 0.006). Tacrolimus trough and normalised trough levels were lower in the graft loss group 73% and 93% of the time, respectively, despite similar tacrolimus doses. Whereas achieving optimal tacrolimus concentration did not significantly affect graft survival, maintaining a haemoglobin level >10 g/dL improved the chances of 3-, 4-, and 5-year graft survival (p-value, 0.001, 0.001, and <0.001, respectively). Patient survival rates were more favourable than graft survival rates. The 1-year and 5-year patient survival rates were 90.0% and 77.4%, respectively. Conclusions: This study offers insights into transplant outcomes in low-resource public health settings. The findings emphasise the impact of rejection and age on the risk of graft failure and the significance of maintaining adequate haemoglobin levels after transplantation. The results also indicate the need for more nuanced and personalised approaches to tacrolimus monitoring in the long-term following transplantation.
- 21 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 132
Open AccessClinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review
Background: Kidney transplantation outcomes in resource-limited settings remain underreported. This 10-year retrospective review examined the clinical characteristics, long-term pharmacokinetics, and outcomes of kidney transplant recipients at a South African public hospital. Methods: Data from kidney transplant recipients between January 2012 and December 2022 were analysed. Graft and patient survival were assessed using Kaplan–Meier analysis. Cox proportional hazards models were used to evaluate the associations between clinical and pharmacokinetic variables and outcomes. Results: The one- and five-year graft survival rates were 87.9% and 65.6%, respectively. Acute rejection, as confirmed by biopsy, was associated with graft failure (HR, 2.46; p = 0.010). Increasing recipient age at transplantation increased the graft failure risk by about 5.0% per year (HR: 1.05, p = 0.006). Tacrolimus trough and normalised trough levels were lower in the graft loss group 73% and 93% of the time, respectively, despite similar tacrolimus doses. Whereas achieving optimal tacrolimus concentration did not significantly affect graft survival, maintaining a haemoglobin level >10 g/dL improved the chances of 3-, 4-, and 5-year graft survival (p-value, 0.001, 0.001, and <0.001, respectively). Patient survival rates were more favourable than graft survival rates. The 1-year and 5-year patient survival rates were 90.0% and 77.4%, respectively. Conclusions: This study offers insights into transplant outcomes in low-resource public health settings. The findings emphasise the impact of rejection and age on the risk of graft failure and the significance of maintaining adequate haemoglobin levels after transplantation. The results also indicate the need for more nuanced and personalised approaches to tacrolimus monitoring in the long-term following transplantation.
- Open Access
- 1 January 2026
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 8 (1) , 1-6
The cost-benefit of utilizing post-dialysis haemoglobin for dosing of erythropoiesis-stimulating agent therapy in patients with anaemia on haemodialysis in a low-resource setting
Background: Access to dialysis in South Africa is limited by budgetary constraints. Erythropoiesis-stimulating agents (ESAs) are used to manage anaemia in dialysis patients but are significant cost drivers. We aimed to evaluate haemoglobin and weight variation during dialysis and to assess whether using post-dialysis haemoglobin rather than pre-dialysis haemoglobin was associated with ESA dose reduction and cost benefit. Methods: In this single-centre cross-sectional study, haemoglobin and weight differences before and after a 4-hour mid-week maintenance haemodialysis session were compared. The ESA doses required to maintain haemoglobin levels within the recommended range of 10 – 11.5g/dL were calculated based on the pre- and post-dialysis haemoglobin results, and the difference was used to determine the cost benefit. Results: Fifty-five patients on chronic haemodialysis at a tertiary hospital in Johannesburg, South Africa, were enrolled. The mean post-dialysis haemoglobin was higher than pre-dialysis haemoglobin (11.34±1.75 vs 10.92±1.45g/dL, p=0.003), representing a 3.95% mean haemoglobin increase. The mean intradialytic weight reduction was 3.32±1.68%, pConclusion: In an environment where dialysis access is limited by resource constraints, ESA dosing based on post-dialysis haemoglobin concentrations may translate into significant cost savings. Larger studies are required to validate this approach and assess long-term patient outcomes.
- 1 January 2026
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 8 (1) , 1-6
Open AccessThe cost-benefit of utilizing post-dialysis haemoglobin for dosing of erythropoiesis-stimulating agent therapy in patients with anaemia on haemodialysis in a low-resource setting
Background: Access to dialysis in South Africa is limited by budgetary constraints. Erythropoiesis-stimulating agents (ESAs) are used to manage anaemia in dialysis patients but are significant cost drivers. We aimed to evaluate haemoglobin and weight variation during dialysis and to assess whether using post-dialysis haemoglobin rather than pre-dialysis haemoglobin was associated with ESA dose reduction and cost benefit. Methods: In this single-centre cross-sectional study, haemoglobin and weight differences before and after a 4-hour mid-week maintenance haemodialysis session were compared. The ESA doses required to maintain haemoglobin levels within the recommended range of 10 – 11.5g/dL were calculated based on the pre- and post-dialysis haemoglobin results, and the difference was used to determine the cost benefit. Results: Fifty-five patients on chronic haemodialysis at a tertiary hospital in Johannesburg, South Africa, were enrolled. The mean post-dialysis haemoglobin was higher than pre-dialysis haemoglobin (11.34±1.75 vs 10.92±1.45g/dL, p=0.003), representing a 3.95% mean haemoglobin increase. The mean intradialytic weight reduction was 3.32±1.68%, pConclusion: In an environment where dialysis access is limited by resource constraints, ESA dosing based on post-dialysis haemoglobin concentrations may translate into significant cost savings. Larger studies are required to validate this approach and assess long-term patient outcomes.
- Open Access
- 24 April 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (3B) , e1240
Pregnancy after kidney and liver transplantation
Pregnancy in kidney and liver transplant recipients presents unique challenges and risks for both maternal and fetal health. This article examines the management of pregnancy in kidney and liver transplant recipients, focusing on pre-pregnancy counselling, trimester-specific care, the teratogenic effects of immunosuppressive drugs, and the role of the multidisciplinary team. While South African (SA) data on this topic are limited, the Transplant Pregnancy Registry International has provided valuable insights. Despite the increased risk of maternal and fetal complications, the overall risk of graft loss during pregnancy is low. Graft survival rates are comparable between pregnant and non- pregnant transplant recipients, except for pregnancies occurring within 1 year of transplantation. By addressing the complexities of managing pregnant women with kidney or liver transplants, this article underscores the importance of tailored care and the involvement of various medical specialists. It also explores the safety of and potential complications associated with specific immunosuppressive therapies during pregnancy. Further research is needed to enhance our understanding and optimise the management of these high-risk pregnancies in SA.
- 24 April 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (3B) , e1240
Open AccessPregnancy after kidney and liver transplantation
Pregnancy in kidney and liver transplant recipients presents unique challenges and risks for both maternal and fetal health. This article examines the management of pregnancy in kidney and liver transplant recipients, focusing on pre-pregnancy counselling, trimester-specific care, the teratogenic effects of immunosuppressive drugs, and the role of the multidisciplinary team. While South African (SA) data on this topic are limited, the Transplant Pregnancy Registry International has provided valuable insights. Despite the increased risk of maternal and fetal complications, the overall risk of graft loss during pregnancy is low. Graft survival rates are comparable between pregnant and non- pregnant transplant recipients, except for pregnancies occurring within 1 year of transplantation. By addressing the complexities of managing pregnant women with kidney or liver transplants, this article underscores the importance of tailored care and the involvement of various medical specialists. It also explores the safety of and potential complications associated with specific immunosuppressive therapies during pregnancy. Further research is needed to enhance our understanding and optimise the management of these high-risk pregnancies in SA.
- Open Access
- 1 January 2023
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 5 (3) , 11-18
Patterns of Glomerular Disease at a Large Urban Public Hospital in South Africa- Impact of HIV Infection
Introduction Glomerular disease is an important cause of renal failure. We sought to describe the patterns of glomerular disease in patients undergoing native kidney biopsy at a large urban public hospital in South Africa during the period 2001–2010. Methods We retrospectively reviewed all native kidney biopsies undertaken during the study period. We further characterised and compared clinical, laboratory and demographic data between glomerular pathologies. Results The majority of patients undergoing biopsy were young (median age 34 years) and of Black African descent (83%). Proteinuria was the most common indication for biopsy. Secondary glomerular disease was more common than primary glomerular disease. HIV-associated glomerular diseases were the most common secondary glomerulopathies Focal segmental glomerulosclerosis (FSGS) was the most frequent primary glomerulopathy. Minimal change nephropathy (MCN) was more frequent in younger patients and membranous nephropathy (MN) more common in older patients. Renal function was poorer in FSGS and membranoproliferative glomerular disease. Conclusions HIV is an important contributor to the high rates of secondary glomerular disease. Primary glomerulopathy demonstrates geographic variation in South Africa with FSGS being dominant in Johannesburg. Although clinical parameters may suggest underlying glomerulopathy, an accurate diagnosis to facilitate directed treatment and prevent progression to renal failure requires a renal biopsy.
- 1 January 2023
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 5 (3) , 11-18
Open AccessPatterns of Glomerular Disease at a Large Urban Public Hospital in South Africa- Impact of HIV Infection
Introduction Glomerular disease is an important cause of renal failure. We sought to describe the patterns of glomerular disease in patients undergoing native kidney biopsy at a large urban public hospital in South Africa during the period 2001–2010. Methods We retrospectively reviewed all native kidney biopsies undertaken during the study period. We further characterised and compared clinical, laboratory and demographic data between glomerular pathologies. Results The majority of patients undergoing biopsy were young (median age 34 years) and of Black African descent (83%). Proteinuria was the most common indication for biopsy. Secondary glomerular disease was more common than primary glomerular disease. HIV-associated glomerular diseases were the most common secondary glomerulopathies Focal segmental glomerulosclerosis (FSGS) was the most frequent primary glomerulopathy. Minimal change nephropathy (MCN) was more frequent in younger patients and membranous nephropathy (MN) more common in older patients. Renal function was poorer in FSGS and membranoproliferative glomerular disease. Conclusions HIV is an important contributor to the high rates of secondary glomerular disease. Primary glomerulopathy demonstrates geographic variation in South Africa with FSGS being dominant in Johannesburg. Although clinical parameters may suggest underlying glomerulopathy, an accurate diagnosis to facilitate directed treatment and prevent progression to renal failure requires a renal biopsy.
- Open Access
- 1 January 2023
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 5 (2) , 129-132
Management of a Jehovah's Witness patient with ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is defined as a systemic autoimmune disease limited to small calibre vasculature, associated with the presence of myeloperoxidase or proteinase 3. After receiving Pfizer BioNTech COVID-19 vaccine a 77-year-old woman of Jehovah's Witness faith presented with renal limited anti-MPO-AAV with underlying iron deficiency anaemia. Treatment was initiated with corticosteroids, iron repletion, Epoetin-beta, renal replacement therapy, plasma exchange with albumin, and cyclophosphamide with successful clearance of ANCA vasculitis. Although Jehovah's Witnesses may refuse transfusion of cellular blood products, they accept and expect alternative effective medical care.
- 1 January 2023
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 5 (2) , 129-132
Open AccessManagement of a Jehovah's Witness patient with ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is defined as a systemic autoimmune disease limited to small calibre vasculature, associated with the presence of myeloperoxidase or proteinase 3. After receiving Pfizer BioNTech COVID-19 vaccine a 77-year-old woman of Jehovah's Witness faith presented with renal limited anti-MPO-AAV with underlying iron deficiency anaemia. Treatment was initiated with corticosteroids, iron repletion, Epoetin-beta, renal replacement therapy, plasma exchange with albumin, and cyclophosphamide with successful clearance of ANCA vasculitis. Although Jehovah's Witnesses may refuse transfusion of cellular blood products, they accept and expect alternative effective medical care.
- 1 December 2022
- Vol. 112 (12) , 919-923
Risk factors and outcomes of sepsis-associated acute kidney injury in intensive care units in Johannesburg, South Africa
Background. Sepsis-associated acute kidney injury (SA-AKI) has been shown to be a significant contributor to morbidity and mortality in both children and adults with critical illness. In sub-Saharan Africa, there is a lack of information on factors associated with development of SA-AKI and outcomes after intensive care unit (ICU) admission.Objectives. To assess the rate of SA-AKI, factors associated with its development, and predictors of mortality at 90 days in critically ill patients admitted to the ICU with sepsis.Methods. This was a prospective observational study conducted at two of the biggest teaching hospitals in Johannesburg, South Africa, from 15 February 2016 to 15 February 2020. The study included consecutive patients with confirmed sepsis who were admitted to the ICU within 24 hours of admission to hospital. The primary outcome of the study was development of SA-AKI (defined according to Kidney Disease Improving Global Outcome (KDIGO) criteria), and secondary outcomes were risk factors for SA-AKI and predictors of mortality at 90 days. Multivariate logistic regression analysis was employed to determine the factors associated with SA-AKI and 90-day mortality.Results. In total, 327 critically ill patients with sepsis admitted to the ICUs were included in the study. The median (interquartile range) age was 39 (30 -52) years, and 185 patients (56.6%) developed SA-AKI. Of these patients, blacks and whites comprised 91.0% and 6.1%, respectively, and the prevalent comorbidities were HIV/AIDS (19.3%), hypertension (14.2%) and diabetes mellitus (10.1%). Patients with SA-AKI were likely to be older and of male gender, and to have cardiovascular disease, malignancies, hypotension and a low serum albumin level. In multivariate analysis, the predictors of SA-AKI were age >= 55 years (odds ratio (OR) 2.43; 95% confidence interval (CI) 1.27 -4.65), inotropic support (OR 3.61; 95% CI 2.18 -5.96) and a low serum albumin level (OR 2.93; 95% CI 1.40 -6.13). SA-AKI and need for inotropic support were respectively associated with 1.9-fold and 1.7-fold increased mortality at 90 days after ICU admission.Conclusion. SA-AKI was found to be frequent in this study in two tertiary hospital ICUs in Johannesburg, and the need for inotropic support predicted mortality after ICU admission.
- 1 December 2022
- Vol. 112 (12) , 919-923
Risk factors and outcomes of sepsis-associated acute kidney injury in intensive care units in Johannesburg, South Africa
Background. Sepsis-associated acute kidney injury (SA-AKI) has been shown to be a significant contributor to morbidity and mortality in both children and adults with critical illness. In sub-Saharan Africa, there is a lack of information on factors associated with development of SA-AKI and outcomes after intensive care unit (ICU) admission.Objectives. To assess the rate of SA-AKI, factors associated with its development, and predictors of mortality at 90 days in critically ill patients admitted to the ICU with sepsis.Methods. This was a prospective observational study conducted at two of the biggest teaching hospitals in Johannesburg, South Africa, from 15 February 2016 to 15 February 2020. The study included consecutive patients with confirmed sepsis who were admitted to the ICU within 24 hours of admission to hospital. The primary outcome of the study was development of SA-AKI (defined according to Kidney Disease Improving Global Outcome (KDIGO) criteria), and secondary outcomes were risk factors for SA-AKI and predictors of mortality at 90 days. Multivariate logistic regression analysis was employed to determine the factors associated with SA-AKI and 90-day mortality.Results. In total, 327 critically ill patients with sepsis admitted to the ICUs were included in the study. The median (interquartile range) age was 39 (30 -52) years, and 185 patients (56.6%) developed SA-AKI. Of these patients, blacks and whites comprised 91.0% and 6.1%, respectively, and the prevalent comorbidities were HIV/AIDS (19.3%), hypertension (14.2%) and diabetes mellitus (10.1%). Patients with SA-AKI were likely to be older and of male gender, and to have cardiovascular disease, malignancies, hypotension and a low serum albumin level. In multivariate analysis, the predictors of SA-AKI were age >= 55 years (odds ratio (OR) 2.43; 95% confidence interval (CI) 1.27 -4.65), inotropic support (OR 3.61; 95% CI 2.18 -5.96) and a low serum albumin level (OR 2.93; 95% CI 1.40 -6.13). SA-AKI and need for inotropic support were respectively associated with 1.9-fold and 1.7-fold increased mortality at 90 days after ICU admission.Conclusion. SA-AKI was found to be frequent in this study in two tertiary hospital ICUs in Johannesburg, and the need for inotropic support predicted mortality after ICU admission.
- Open Access
- 1 January 2021
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 3 (2) , 141
The “Plagues” of 2020/2021: Viral Pandemic and a Fire
In 1472, Dante Alighieri, in part one of the Divine Comedy, aptly named Inferno, wrote “lasciate ogne speranza, voi ch’intrate”. These words were translated in 1814 to “abandon all hope ye who enter here” – the famous words in the poem inscribed above the gates of Hell.
- 1 January 2021
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 3 (2) , 141
Open AccessThe “Plagues” of 2020/2021: Viral Pandemic and a Fire
In 1472, Dante Alighieri, in part one of the Divine Comedy, aptly named Inferno, wrote “lasciate ogne speranza, voi ch’intrate”. These words were translated in 1814 to “abandon all hope ye who enter here” – the famous words in the poem inscribed above the gates of Hell.
- Open Access
- 8 February 2015
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 105 (3) , 237
Management of patients with chronic kidney disease
Management of patients with chronic kidney disease
- 8 February 2015
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 105 (3) , 237
Open AccessManagement of patients with chronic kidney disease
Management of patients with chronic kidney disease